Car­lyle’s Abing­worth will help fund Te­va’s Phase 3 asth­ma res­cue in­haler

Abing­worth will pro­vide up to $150 mil­lion to help fund Te­va Phar­ma­ceu­ti­cals’ de­vel­op­ment of an asth­ma res­cue in­haler, the com­pa­nies said Mon­day morn­ing.

The as­set, known as ICS-SA­BA/TEV-’248, en­tered Phase 3 test­ing last fall and will have re­sults in the sec­ond half of 2026, ac­cord­ing to a Te­va pre­sen­ta­tion from Jan­u­ary.

The in­haler could work for adults and chil­dren, Te­va has said. It com­bines the “two most wide­ly used mol­e­cules,” which are flu­ti­ca­s­one pro­pi­onate and al­buterol sul­fate. The Is­rael-based phar­ma in Jan­u­ary tout­ed a $2.5 bil­lion po­ten­tial mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER